+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 55Years
All Genders
Healthy Volunteers
ID07758985

Evaluating Safety, Tolerability, Pharmacokinetics, and Mosquitocidal Activity of Single Oral Doses of Lotilaner in Healthy Adults in Mali A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study

Led by Medicines for Malaria Venture · Updated on 2026-09-24

75

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a Phase 1b, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and mosquitocidal activity of single oral doses of lotilaner in healthy adults living in Mali. This study aims to provide proof-of-concept data on lotilaners effects and behavior in the body when given to adults aged 18 to 55. The study involves three staggered groups of 25 participants each. Participants are randomized in a 41 ratio to receive either a single dose of lotilaner or placebo. The doses vary by cohort, including a low dose with a high-fat meal, a high dose in a fasted state, and a high dose with a high-fat meal. The dosing occurs on Day 1, and the next group starts only after safety and tolerability are reviewed for at least 8 days from the previous group. Blood samples will be collected regularly over about 6 months to assess safety, drug levels, and the bloods ability to kill mosquitoes. Participants will visit the clinical unit for follow-up visits according to the assessment schedule for approximately six months. During these visits, blood will be tested for safety and pharmacokinetic analyses. Mosquitocidal efficacy will be evaluated using mosquito membrane feeding assays on collected blood samples. The main outcome measured is the safety and tolerability of lotilaner from dosing through Day 169, along with various pharmacokinetic and mosquito survivorship assessments.

CONDITIONS

Brief Title

Safety, Tolerability, Pharmacokinetics, and Mosquitocidal Activity of Lotilaner in Healthy Participants in Mali.

Research Team

H

Helen Demarest

P

Peya Gaye

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here